Synonyms: example A1 [US2014011819] | RP-5264 | RP5264 | TGR-1202 | TGR1202 | Ukoniq®
umbralisib is an approved drug (FDA (2021))
Compound class:
Synthetic organic
Comment: Umbralisib (TGR-1202; RP5264,) is an orally available, selective inhibitor of the δ isoform of phosphoinositide 3-kinase (PI3K) [1,3,5], that was developed by TG Therapeutics for the treatment of several B cell malignancies. It also inhibits casein kinase-1ε [2]. For clinical application umbralisib is formulated as the tosylate salt.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Umbralisib is >1000-fold selective against PI3Kα, >54-fold selective against PI3Kβ and >9-fold selective against PI3Kγ [5]. It also inhibits casein kinase-1ε (CSNK1E; by 60% at 1 μM), which is a major regulator of protein translation [3]. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|